News Sentiment

DGX sentiment intelligence

Quest Diagnostics Incorporated news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 62 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Diagnostics & Research Read-through group
Latest close 210.68 Week of 17 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend active

+1.6% over one week, +8.5% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Quest Diagnostics stock trades steadily as investors weigh recent revenue growth and dividend income

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 1.6% Price digesting
Trend fit Trend active 8.5% over four weeks
Fair value 33.3% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 37
Negative 2

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Ad-hoc-news.de 9
TradingView 9
Market source 5
PR Newswire 4
MarketWatch 3
simplywall.st 3
Ad Hoc News 3
DirectorsTalk Interviews 3

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 17
Analyst action 6
Capital return 3
Macro sensitivity 2
Regulatory and legal 2
Deals and strategy 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Ad-hoc-news.de Direct company coverage

Quest Diagnostics stock trades steadily as investors weigh recent revenue growth and dividend income

Quest Diagnostics stock reflects steady fundamentals, with investors focusing on recent revenue trends, earnings resilience, and cash returns via dividends alongside the broader US healthcare diagnostics sector. The company's financials show moderate revenue growth, stable earnin

Tone
Positive 71/100
Event
Earnings
Published
21 Jul 2026 16:13
Source
Ad-hoc-news.de
TradingView Direct company coverage

DGX4807226 Bond Coupon Profile — Rate & Payments

This article provides the coupon profile for the DGX4807226 bond issued by Quest Diagnostics Incorporated. It details that the current coupon rate is 4.20% and the next payment is scheduled for December 31, 2026. The article highlights the bond's interest payment overview and off

Tone
Neutral 50/100
Event
Market update
Published
21 Jul 2026 10:07
Source
TradingView
MarketWatch Direct company coverage

Quest Diagnostics Inc. stock underperforms Monday when compared to competitors

Shares of Quest Diagnostics Inc. (DGX) fell 1.43% on Monday, closing at $207.66. This underperformance occurred on a generally negative trading day, with both the S&P 500 Index and Dow Jones Industrial Average also declining. The stock's drop ended a two-day winning streak.

Tone
Negative 36/100
Event
Market update
Published
20 Jul 2026 20:37
Source
MarketWatch
MedTech Dive Direct company coverage

Tempus to buy cancer test-maker Personalis for $1.5B

Tempus AI has announced an agreement to acquire Personalis, a maker of molecular residual disease tests for cancer, for $1.5 billion. This acquisition is expected to enhance Tempus's capabilities in cancer diagnostics, treatment selection, recurrence, and monitoring, building on

Tone
Positive 61/100
Event
Deals and strategy
Published
20 Jul 2026 19:09
Source
MedTech Dive
AlphaStreet Direct company coverage

Quest Diagnostics Q2 2026 Earnings Preview — July 23, Street Expects $2.82 EPS

Wall Street anticipates Quest Diagnostics will report Q2 2026 earnings of $2.82 per share on revenue of $2.97 billion, with the announcement expected on July 23. This projection reflects a 7.6% increase in both EPS and revenue compared to Q2 2025 results. Analysts will be closely

Tone
Neutral 50/100
Event
Earnings
Published
20 Jul 2026 13:37
Source
AlphaStreet
ad-hoc-news.de Direct company coverage

Quest Diagnostics stock trades steady as investors weigh recent earnings and volume trends

Quest Diagnostics stock is trading steadily as investors assess its recent earnings and volume trends, driven by diagnostic testing demand and margin performance. The company's financial health is supported by resilient testing volumes, cost-management initiatives, strong cash fl

Tone
Positive 61/100
Event
Earnings
Published
20 Jul 2026 09:44
Source
ad-hoc-news.de
Moomoo Direct company coverage

Quest Diagnostics | SCHEDULE 13G/A: Others

This article is a financial filing document, specifically a SCHEDULE 13G/A, related to Quest Diagnostics. The "Others" designation suggests a filing by a category of investor other than an institutional manager, perhaps an individual or a passive investor group revealing benefici

Tone
Neutral 50/100
Event
Market update
Published
19 Jul 2026 08:07
Source
Moomoo
TradingView Direct company coverage

DGX4986719 Bond Risk Profile

This article provides a risk profile for the Quest Diagnostics Incorporated 2.8% bond, identified as DGX4986719. It highlights key metrics for assessing credit risk, such as security level, inflation protection, and issuer rating. The profile aims to help investors evaluate the b

Tone
Neutral 50/100
Event
Analyst action
Published
18 Jul 2026 19:07
Source
TradingView
Sahm Direct company coverage

The Bull Case For Quest Diagnostics (DGX) Could Change Following Oncology Test Integration Into OncoEMR - Learn Why

Quest Diagnostics recently integrated its Haystack MRD ctDNA test and Comprehensive Genomic Profiling services into Flatiron Health’s OncoEMR, granting 4,700 clinicians easier access to these oncology tests. This move positions Quest as the largest reference lab to integrate adva

Tone
Positive 72/100
Event
Market update
Published
18 Jul 2026 04:08
Source
Sahm
ad-hoc-news.de Direct company coverage

Quest Diagnostics stock holds near results driven levels

Quest Diagnostics stock performance is being evaluated based on its recent earnings metrics, including quarterly revenue of $2.62 billion, adjusted diluted EPS of $2.64, and an adjusted operating margin of 15.0%. The company's core diagnostic testing franchise is its primary earn

Tone
Neutral 50/100
Event
Earnings
Published
18 Jul 2026 03:02
Source
ad-hoc-news.de
TradingView Direct company coverage

ETFs Investing in Quest Diagnostics Incorporated Stocks

This article lists various Exchange Traded Funds (ETFs) that hold Quest Diagnostics Incorporated (DGX) stocks. It provides a detailed table including each fund's market value, weight

Tone
Neutral 50/100
Event
Market update
Published
17 Jul 2026 07:07
Source
TradingView
Ad Hoc News Direct company coverage

Quest Diagnostics stock trades steadily as investors weigh steady revenue and margin trends

Quest Diagnostics stock reflects a balance between stable revenue growth and margin pressures. Recent financial results show the company managing the transition from pandemic-related testing to routine services, maintaining mid-single-digit revenue growth and mid-teens operating

Tone
Positive 63/100
Event
Earnings
Published
17 Jul 2026 03:33
Source
Ad Hoc News
MarketWatch Direct company coverage

Quest Diagnostics Inc. stock outperforms competitors on strong trading day

Quest Diagnostics Inc. (DGX) shares rose 3.79% to $209.41 on Thursday, outperforming the broader market which saw the S&P 500 Index fall 0.51% and the Dow Jones Industrial Average decline 0.20%. This gain broke a nine-day losing streak for the company's stock.

Tone
Positive 66/100
Event
Market update
Published
16 Jul 2026 22:37
Source
MarketWatch
TradingView Direct company coverage

DGX.GL Bond Profile — Key Metrics

This article provides key metrics for the DGX.GL bond, issued by Quest Diagnostics, Inc. The bond has a 5.75% coupon rate and matures on January 30, 2040, with an outstanding amount of $249.24 million. Quest Diagnostics, Inc. is a diagnostic testing and information services compa

Tone
Neutral 50/100
Event
Market update
Published
16 Jul 2026 14:37
Source
TradingView
Ad Hoc News Direct company coverage

Quest Diagnostics stock holds steady as diagnostics demand underpins long term growth

Quest Diagnostics stock reflects the company's significant position as a major US clinical laboratory operator, benefiting from a steady, long-term demand for diagnostic services. The company's large-scale network, operational efficiency, and role in chronic disease management an

Tone
Positive 75/100
Event
Macro sensitivity
Published
16 Jul 2026 11:58
Source
Ad Hoc News
MarketWatch Direct company coverage

Quest Diagnostics Inc. stock underperforms Wednesday when compared to competitors

Shares of Quest Diagnostics Inc. (DGX) fell 2.05% on Wednesday, closing at $201.77. This underperformance occurred despite a favorable trading session for the broader market, with both the S&P 500 Index and the Dow Jones Industrial Average posting gains. This marked the ninth con

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 17:03
Source
MarketWatch
Moomoo Direct company coverage

Quest Diagnostics Currently Down Nine Consecutive Days, on Pace for Longest Losing Streak Since September 2001 -- Data Talk

Quest Diagnostics (DGX) has experienced a nine-day losing streak, its longest since September 2001, and is currently trading down 0.7% at $139.12. Despite this recent downturn, the stock has seen a 1-month gain of 0.77%, but a 6-month loss of 1.13%, and is down 2.87% year-to-date

Tone
Negative 27/100
Event
Market update
Published
15 Jul 2026 14:37
Source
Moomoo
TradingView Direct company coverage

A4ET8Q Bond Profile — Key Metrics

This article provides key metrics for the A4ET8Q bond, issued by Quest Diagnostics, Inc. The bond has a 5.0% coupon rate, an issue date of May 6, 2026, and matures on June 30, 2036. Quest Diagnostics, Inc. specializes in diagnostic testing and information services through its Dia

Tone
Neutral 50/100
Event
Market update
Published
15 Jul 2026 12:08
Source
TradingView
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: Medtronic (MDT), Quest Diagnostics (DGX) and Gilead Sciences (GILD)

Three analysts from Bank of America Securities have provided bullish sentiments on healthcare companies Medtronic (MDT), Quest Diagnostics (DGX), and Gilead Sciences (GILD). Travis Steed maintained a Buy rating on Medtronic with a $95.00 price target, Michael Ryskin kept a Buy ra

Tone
Positive 70/100
Event
Analyst action
Published
15 Jul 2026 04:37
Source
The Globe and Mail
TradingView Direct company coverage

US74834LBG4 Bond Profile — Key Metrics

This article provides a detailed profile of the Quest Diagnostics Incorporated 5.0% 15-DEC-2034 bond, identified by the ISIN US74834LBG4. Key metrics such as issue date, maturity date, outstanding amount, face value, and coupon rate are presented. It also includes a brief descrip

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 23:37
Source
TradingView
TradingView Direct company coverage

A28XES Bond Risk Profile

This article provides a risk profile for the A28XES bond issued by Quest Diagnostics Incorporated. It highlights key metrics for credit risk assessment, including security level, inflation protection, and issuer rating, to help investors evaluate the bond's reliability. The bond

Tone
Neutral 50/100
Event
Analyst action
Published
14 Jul 2026 16:37
Source
TradingView